Long-term double-blind study of the efficacy of intermitent nasal elcatonin in recent postmenopausal women;Estudio doble ciego sobre la eficacia de elcatonina nasal intermitente a largo plazo en mujeres postmenopáusicas recientes

Anales de Medicina Interna

Volumn 17, Issue 8, 2000, Pages 399-405

  Lozano Tonkin, C ^a   Gracia Canales, A ^a   Jareno J ^a   Mercadal, J ^a  

^a Centro de Investigaciones Farmaceuticos Grupo Ferrer   (Spain)

Author keywords

Bone mass; Bone mineral density; Clinical trial; Double blind; DXA, elcatonin; Long term; Osteopenia, Postmenopause; Randomised

Indexed keywords

ELCATONIN;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANALYSIS OF VARIANCE; BONE DENSITY; CALCITONIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUMBOSACRAL REGION; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 0034460986     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Consensus development conference: Prophylaxis and treatment of osteoporosis
2. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin
3. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment
4. Long-term calcitonin therapy in postmenopausal osteoporosis
5. Time course of "escape" from calcitonin-induced inhibition of motility and resorption of disaggregated osteoclasts
6. Long-term treatment with calcitonin in osteoporosis
7. Clinical significance of antibodies against calcitonin
8. Therapeutic strategies in osteoporosis: Whom to treat and when. Treatment of postmenopausal bone loss: Long-term strategies
9. Calcitonine et vieillissement osseux
10. Long-term treatment of established osteoporosis with intranasal calcitonin
11. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report
12. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease
13. What should be done at the time of menopause?
14. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study
15. Use of calcitonin in 20 patients suffering from postmenopausal osteoporosis. A proposal for a therapeutical scheme
16. Comparative effects on bone mineral content of calcium and calcium plus salmón calcitonin given in two different regimens in postmenopausal osteoporosis
17. Salmon calcitonin (injection and nasal spray) and placebo in patients undergoing total hip replacement: A double-blind study
18. Efficacy and safety of two elcatonin regimens in the treatment of osteoporosis
19. Effectiveness and safety of medium and long-term elcatonin use in the prevention and treatment of bone mass loss
20. Profhylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: Comparative longitudinal study of bone mass
21. Long-term treatment of established osteoporosis with intranasal calcitonin
22. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss
23. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study
24. Intranasal salmon calcitonin in postmenopausal osteoporosis: Effect of different therapeutic regimens on vertebral and peripheral bone density
25. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin
26. Long-Term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin
27. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
28. Patient responsiveness to calcitonin salmon nasal spray: A subanalysis of a 2-year study
29. Salmon calcitonin in the prevention of bone loss at perimenopause
30. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
31. Effect of different doses of nasal salmon calcitonin on bone mass
32. A double blind placebo controlled trial of the efficacy and tolerability of intranasal elcatonin administered to patients suffering from senile and postmenopausal osteoporosis
33. Prevenzione della osteoporosi postmenopausale con basse dosi di carbocalcitonina spray nasale
34. Dos estudios de diseño doble ciego controlados con placebo sobre la eficacia y seguridad del spray nasal de elcatonina a dosis de 40 UE/día en mujeres postmenopáusicas
35. Tratamento con carbocalcitonina e alfacalcidolo in donne con densità ossea radiale ridotte
36. Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis
37. Calcitonin and its antinociceptive activity: Animal and human investigations 1975-1992
38. Calcitonin and beta-endorphin secretion
39. Antalgic activity of calcitonin: Effectiveness of the epidermal and subarachnoid routes in man
40. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: A double-blind, double-placebo study
41. Double-blind, placebo-controlled study of salmon calcitonin's potentiation of morphine's analgesic effect against cancer pain
42. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study
43. Effect of treatment with synthetic eel-calcitonin derivative in patiens suffering pain due to bone metastases
44. Il dolore nell'osteoporosi postmenopausale: Profilo dell'azione analgesica della calcitonina spray nasale
45. Analgesisc effect of elcatonin in postmenopausal osteoporosis
46. Antinociceptive effects of repeated systemic injections of calcitonin in formalin-induced hyperalgesic rats
47. Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic el calcitonin
48. Post-menopausal osteoporosis: Therapeutic and side effects of different calcitonins
49. Long -and short- term side effects and safety of calcitonin in man: A prospective study
50. Clinical study on activity and tollerability of carbocalcitonin (Asu 1,7) E-CT in the treatment of patients with different bone diseases
51. Elcatonin in the treatment of osteoporosis: Results of a postmarketing surveillance study
52. Long-term tolerability of nasal spray formulation of salmon calcitonin
53. Tolerabilità localle della carbocalcitonina dopo somministrazione per instillazione intranasale
54. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
55. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Further interim results of the "PROOF" study